Elucent Medical develops guided surgical technologies that transform standard instruments into smart tools using its In-Body Spatial Intelligence (iSi) platform. Its flagship EnVisio System uses a spatial field generator to measure continuous data points across multiple planes and displays exact 3D positioning of the SmartClip marker and SmartSensor to guide soft-tissue surgical excision. EnVisio's adaptive design is intended to integrate seamlessly into surgical workflows to provide intuitive, uninterrupted 3D surgical awareness and improved precision. The company positions its technology for surgical oncologic care to improve patient outcomes through greater accuracy. Elucent is based in Eden Prairie, Minnesota. In 2024 it raised $44.0 million in a Series C, and in January 2025 Trinity Capital committed $30 million in growth capital to support scaling operations, innovation, and commercialization. Elucent Medical, led by President and CEO Jason Pesterfield and based in Eden Prairie, MN, develops surgical navigation technologies for soft tissue oncology. Its flagship products, EnVisio and SmartClip, provide intelligent spatial guidance by converting existing surgical tools into tracked, real‑time navigated instruments with millimeter precision. EnVisio is currently optimized for guiding breast cancer surgery and adoption has expanded into other soft tissue oncologic procedures. The company is developing additional products to help surgeons achieve margin‑negative resections in lung and other soft tissue clinical applications. Its solutions are designed to integrate with existing tools and minimally invasive platforms, including video and robotic‑assisted technologies. Elucent intends to commercialize and further develop these technologies to improve targeting and tissue‑sparing oncologic surgery.

Total raised

$73M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2025